Clinical trial NCT05324501: A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma
Official title: Phase I Open Label Ascending Dose Study to Assess the Feasibility and Safety of Intermittent Infusions of MTX110 Administered by Convection-Enhanced Delivery (CED) in Patients With Recurrent Glioblastoma (rGBM) (MAGIC-G1)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Recurrent Glioblastoma
Lead sponsor: Biodexa Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2022-04-12
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Two cohort 3+3 design. Between 4-18 patients per cohort.
Primary purpose: TREATMENT

Brief summary: A study designed to assess the safety of MTX110 in patients suffering with recurrent glioblastoma. MTX110 will be administered directly to the site of the tumour via a catheter which is inserted during a surgical procedure at the beginning of the study.

Detailed description: A two cohort, ascending dose study of intra-tumoral MTX110 in patients with recurrent glioblastoma. With the aim to assess the safety and also the recommended phase 2 dose of MTX110.

The patient will undergo a surgical procedure to insert a programmable pump and catheter system to allow administration of MTX110 directly to the tumour using Convection Enhanced Delivery (CED).

Cohort A patients will receive one of three potential dose levels of MTX110 as a weekly infusion in order to establish recommended phase 2 dose. This will be based on an accelerated dose titration/3+3 design.

Cohort B patients will follow the 3+3 study design with the starting concentration established in Cohort A. They too will receive MTX110 as a weekly infusion and may undergo catheter repositioning and continued treatment following progression.

Eligibility criteria: Inclusion Criteria:

* Recurrent glioblastoma.
* Patients must be healthy enough to tolerate surgery and general anesthesia.
* Estimated life expectancy of greater than 3 months.

Exclusion Criteria:

* Patients scheduled to undergo or are undergoing re-irradiation for the recurrent tumour.
* Patients with a history of glioblastoma treatment with carmustine or Gliadel® wafers.
* Patients who cannot undergo MRI.
* Patients may not have received chemotherapy or bevacizumab ≤ 4 weeks, or metronomic dosed chemotherapy such as daily etoposide or cyclophosphamide (1 week) prior to starting the study drug.
* Patients may not have received treatment with tumor treating fields ≤ 1 week prior to starting the study drug.
* Patients may not be less than 12 weeks from completion of radiation therapy for the primary tumor.
* Patients with neoplastic lesions in the brainstem, cerebellum, or spinal cord; radiological evidence of active; multifocal disease; extensive subependymal disease (tumor touching subependymal space is allowed); tumor crossing the midline or leptomeningeal disease.
* Posterior fossa location of the tumor, regardless of its morphology.
* Prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin (treatment with tamoxifen or aromatase inhibitors or other hormonal therapy that may be indicated in prevention of prior cancer disease recurrence, are not considered current active treatment).

Primary outcomes:
measure: Safety of MTX110 administered by CED
timeFrame: Through study completion, an expected average of 28 weeks. DLT period 28 days from first dose.
measure: To determine the recommended Phase 2 dose (RP2D) of MTX110
timeFrame: Through study completion, an expected average of 28 weeks
Secondary outcomes:
measure: Overall survival
timeFrame: 12 months
measure: Progression-free survival
timeFrame: 6 months
measure: Best overall response rate
timeFrame: 6 months
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Baptist MD Anderson
state: Florida
city: Durham
country: United States
facility: Duke University Hospital
state: North Carolina
Study officials:
affiliation: Biodexa Pharmaceuticals
name: Gary Shangold
role: STUDY_DIRECTOR
References: